College of Medicine
Louie Lab
Led by Arnold Louie · Medicine
What we study
The Louie Lab studies Gram-negative bacteria and tuberculosis, focusing on developing new treatments and optimizing drug combinations to combat infections. They work on both experimental and clinical approaches.
What working here is like
- Wet lab
- Bacteria & microbes
- Projects
- 2
- Papers
- 5
Current projects
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in…
Developing new treatments for Gram-negative bacteria causing ventilator-associated pneumonia.
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
Improving tuberculosis treatments to speed up recovery and reduce resistance.
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations
2026 · PLoS ONE
Tests new drug combinations for tuberculosis to speed up treatment and reduce resistance.
- Humanizing meropenem dosage regimens by co-administration of cilastatin in an immunocompetent mouse bloodstream infection model of Acinetobacter baumannii based on a novel quantitative matching framework
2026 · Journal of Antimicrobial Chemotherapy
Creates mouse drug doses that mimic human levels for meropenem, using cilastatin to extend its effects.
Show 3 more papersShow fewer
- Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model
2025 · Journal of Antimicrobial Chemotherapy
Compares apramycin and amikacin to treat M. abscessus in a lab model.
- Analyzing Pharmacodynamic Count Data That Rapidly Decrease to Zero
2025 · CPT Pharmacometrics & Systems Pharmacology
Develops a method to analyze how quickly bacteria die after treatment in lab tests.
- Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125–1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea
2024 · Journal of Antimicrobial Chemotherapy
Tests single-dose ceftriaxone for gonorrhea, including resistant strains, in a lab model.
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Arnold Louie hasn't set up this page yet. Their UF Scholars profile lists their publications.